Limitations in LC-MS/MS application for adagrasib and pembrolizumab quantification in rat plasma

An article by Harsha Shi et al. raises multiple concerns regarding sample preparation, the presence of the analyte in the analyzed solution, authenticity of the MS spectra, administration of drugs and blood collection, choice of internal standard, obtained pharmacokinetic parameters and usage of chromatographic column and solvents. While the research topic is interesting and the development of bioanalytical methods for novel drugs is crucial, this article does not seem to meet the analytical and methodological standards for the reliable determination of adagrasib and pembrolizumab in plasma samples. A detailed explanation is given in the letter.